NCT06678542View on ClinicalTrials.gov

Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

February 16, 2025

Study Completion Date

February 16, 2025

Conditions
Healthy Participants
Interventions
DRUG

GP681 tablet

GP681 tablet, 20 mg, single oral dose in each Group.

DRUG

GP681 Powder for Oral Suspension

GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.

Trial Locations (1)

Unknown

Women and Children's hospital of Ningbo University, Ningbo

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY

NCT06678542 - Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects | Biotech Hunter | Biotech Hunter